Showing 101 - 120 results of 142 for search '"University of Texas MD Anderson Cancer Center"', query time: 0.05s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114
  15. 115
  16. 116
  17. 117

    Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States by Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO

    Published 2025-02-01
    “…Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA; 4Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 5Department of Medicine, University of Florida Health, Gainesville, FL, USA; 6US Medical Affairs, Oncology, Bayer Healthcare, Whippany, NJ, USA; 7Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Richard S Finn, Department of Medicine, University of California, Los Angeles, CA, USA, Tel +1-310-586-2091, Email rfinn@mednet.ucla.eduIntroduction: While several systemic therapies are available for unresectable hepatocellular carcinoma (uHCC), there is a lack of granular real-world evidence to support the efficacy and safety of these therapies. …”
    Get full text
    Article
  18. 118
  19. 119
  20. 120